Navigation Links
Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
Date:12/2/2007

he NP-1 trial in DPN, there are two other clinical trials for NP-1 currently underway.

-- A Phase III trial in chemotherapy-induced peripheral neuropathy (CPN)

is being conducted by the National Cancer Institute (NCI)-funded

Community Clinical Oncology Program. The double-blind, randomized

placebo-controlled study includes approximately 400 patients suffering

from painful CPN for at least 28 days following the conclusion of

chemotherapy. The primary endpoint of the 12-week trial is change in

average daily pain intensity scores from baseline to the endpoint.

This trial is currently enrolling patients.

-- A Phase IIb trial is underway in peripheral herpetic neuropathy. This

500-patient, placebo- and active-controlled trial will compare the

efficacy and safety of NP-1 vs. gabapentin and placebo. The primary

endpoint for this trial is the change in pain intensity over the four-

week duration of the trial. Preliminary results are expected early in

the second quarter of 2008.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company's broad portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is approaching a decision in Europe. In addition, EpiCept's ASAP technology, a proprietary live cell high- throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.

Forward-Looking Statements

<
'/>"/>
SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Dec. 17 The Department of Justice ... state of New York have entered into settlement ... allegations that they submitted false claims to the ... The New York Medicaid program provides coverage for ... valid certificates showing that they received proper training. ...
(Date:12/17/2009)... Life" in Majority Leader,s Revisions to Senate Health ... 17 Americans United for Life Action ... to Senate Majority Leader Harry Reid as he ... revisions to a bill - to the Senate ... to include "specific language that ensures your legislation ...
(Date:12/17/2009)... ,Hopenhagen, the city is calling itself, ... international conference on climate change. Narconon has its ... of the worldwide Narconon drug education ... from climate change. But the streets thrum with ... by with flashing blue lights - a youth ...
(Date:12/17/2009)... not be beneficial , , THURSDAY, Dec. 17 (HealthDay News) ... the immediate effect of the fish oil fatty acids ... increase in blood fats and the molecules that help ... that the acute response has some potentially negative effects ... long-term intake," said Lindsay E. Robinson, an associate professor ...
(Date:12/17/2009)... fall down on prevention, experts say , , THURSDAY, ... surgeons are getting better at treating heart attacks ... ignoring the basic rules for preventing them, according ... , Topping the list: too little exercise, too ... adults surveyed last year reported no activity vigorous ...
Breaking Medicine News(10 mins):Health News:Three New York City Home Health Agencies Pay $9.7 Million to the United States to Settle False Claims Act Claims 2Health News:Pro-Life Leader Sends Urgent Letter to Senator Reid 2Health News:Save the Planet. Stop Smoking Dope, Says Narconon 2Health News:Could Omega-3s Boost Blood Fat Levels? 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 3
... support program with the goal to help healthcare professionals optimize outcomes ... ... (PRWEB) January 29, 2009 -- Though rare, gastrointestinal stromal tumors (GISTs) ... with an estimated 3,300 to 6,000 new cases reported each year ...
... message during the big gameMINNEAPOLIS, Jan. 29 The ... ads as it is for the actual football game. ... from ClearWay Minnesota that somberly reminds Minnesotans that "we ... and health consequences of tobacco use are explored though ...
... Researchers from Boston University School of Medicine (BUSM) and ... have found that children born more than three months premature, ... the modified checklist for autism in toddlers (M-CHAT). Children ... for developing autism. These findings appear in the January ...
... A new way of making LEDs could see household ... years. , Gallium Nitride (GaN), a man-made semiconductor ... light but uses very little electricity. Until now high ... wide spread use in homes and offices. , ...
... years; lawmakers demand criminal probe after U.S. health officials ... 2007 and 2008. , , WEDNESDAY, Jan. 28 (HealthDay News) ... late Wednesday for all peanut products made over the ... the current salmonella outbreak. , The recall was initiated ...
... Jan. 28 Consumer Watchdog warned that the move by ... California will lead to degradation of the quality of patient ... the interest of nursing home owners over patients.The current agreements ... protect the right of caregivers to blow the whistle on ...
Other Medicine News:Health News:Novartis Oncology Launches GIST Alliance&#8482; for Healthcare Professionals Treating Gastrointestinal Stromal Tumors 2Health News:Novartis Oncology Launches GIST Alliance&#8482; for Healthcare Professionals Treating Gastrointestinal Stromal Tumors 3Health News:New Super Bowl Ad Reminds Minnesotans: 'We All Pay the Price for Tobacco' 2Health News:New Super Bowl Ad Reminds Minnesotans: 'We All Pay the Price for Tobacco' 3Health News:Study finds preemies more likely to score positive 2Health News:Low-cost LEDs to slash household electric bills 2Health News:All Products at Georgia Peanut Plant Recalled 2Health News:All Products at Georgia Peanut Plant Recalled 3Health News:All Products at Georgia Peanut Plant Recalled 4
(Date:12/17/2009)... 17 Instacare Corp. (OTC Bulletin Board: ... life-enhancing prescription drugs and diagnostics and at home ... leading developer and provider of e-health technologies and ... today that as part of the preparation of ... to add two new Directors and has rejected, ...
(Date:12/17/2009)... -- Express Scripts, Inc. (Nasdaq: ESRX ... management companies in North America, announced today ... association of seizure risk among epilepsy patients ... The study found no evidence that switching ... generic substitution, was associated with increased emergency ...
(Date:12/17/2009)... BioTherapeutics, Inc. (NYSE-Amex: PLX ) today announced ... Sales and Commercial Affairs. In this newly ... responsible for all commercial activities, including pre-launch and ... the collaboration agreement between the Company and Pfizer ... emerge from the Company,s pipeline. Ms. Lauterbach ...
Breaking Medicine Technology:Instacare Corp. Board of Directors Sets Growth Plans for 2010 2Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity 2Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 2Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 4Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 1Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 2Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 3Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 1Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 2Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 1Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 2
... Abeome Corporation, a,Georgia-based biotech company, announced today ... a collaboration with Cato Research Ltd.,its global ... collaboration will help support continued development of ... technology vastly improves the development of,monoclonal antibodies ...
... as the Clinical Gold Standard ... from Decision Resources, WALTHAM, Mass., July 15 ... and advisory firms focusing on pharmaceutical and,healthcare issues, ... of depressive mood episodes in patients who suffer ...
Other Medicine Technology:Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic 2Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder 2
Inquire...
... Array Multifocal IOL was designed to provide ... from glasses in most situations. While distance ... similar to that of a single vision ... better and about 19 in 20 people ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... The Zeus Scientific, Inc. ... for the qualitative and quantitative ... human serum by the indirect ... assay can determine or confirm ...
Medicine Products: